Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eye-Catching Insider Selling at Ross Stores, Celgene Corporation, Copart; Two Other Companies Register Insider Buying

Extensive research shows that corporate insiders tend to make more profit-generating trades than the average non-insider, which serves as the primary reason Insider Monkey, retail investors, analysts and hedge funds have been keeping track of insider trading metrics for years. However, insider selling does not necessarily represent a bearish or negative signal; this kind of insider trading activity needs to be interpreted with high caution.

After all, corporate insiders may cash out holdings for cash needs, tax payments or other reasons unrelated to their companies’ current fundamentals or future prospects. Hence, Insider Monkey does not recommend acting or trading immediately on each freshly-detected insider sale, but rather attempt to complete a more thorough analysis of the companies witnessing insider selling to clarify whether insider sales are indeed cause for concern. In other words, the analysis of insider selling should merely serve as a tool in assessing the potential of a stock. That said, the following article will discuss a set of noteworthy insider sales reported with the SEC on Monday, as well as discuss some mild insider buying observed at two other companies.

Through extensive research that covered the portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

Insider Trading Wall Street Stock Market Dow Jones bank benefit business capital chart company corporate

Francisco Amaral Leitao /

CSO and CFO of Battered Biotechnology Company Purchase Shares

Two top-tier executives at Applied Genetic Technologies Corp (NASDAQ:AGTC) purchased shares in the past few weeks. To start with, Chief Scientific Officer Mark S. Shearman purchased a new stake of 3,000 shares on Thursday at a weighted average price of $8.87 per share. Lawrence E. Bullock, Chief Financial Officer since February 2014, snapped up a 10,000-share stake last Monday at a price tag of $8.75 each.

The clinical-stage biotechnology company that uses gene therapy to develop genetic therapies to treat patients with inherited diseases has seen the value of its shares plunge by 56% since the start of the year. Applied Genetic Technologies Corp (NASDAQ:AGTC)’s shares took a serious hit earlier this month, when the company released its financial results for its fiscal-fourth-quarter that ended June 30 and simultaneously provided updates on its ongoing clinical trials. The negative reaction from Wall Street appears to have been related to the company’s clinical updates. The company’s most advanced products are being developed to deal with three inherited orphan diseases of the eye that are caused by mutations in single genes that impact visual functions. Jim Simons’ Renaissance Technologies LLC owned 119,600 shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) at the end of the second quarter.

Follow Applied Genetic Technologies Corp (NASDAQ:AGTC)
Trade (NASDAQ:AGTC) Now!

The next two pages of this article will discuss a number of other insider transactions reported with the SEC on Monday.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.